Faculty Profiles - KANDA Mitsuro

Papers - KANDA Mitsuro

Division display 201 - 220 of about 573 ／ All the affair displays >>

DAA時代のHCV治療がもたらす切除可能HCCへの臨床的影響の検討 Reviewed

園原史訓, 山田豪, 高見秀樹, 猪川祥邦, 林真路, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本消化器外科学会総会 Vol. 75回 page： O12 - 3 2020.12

尿中cell free DNAを用いた膵癌診断法の開発 Reviewed

林真路, 山田豪, 高見秀樹, 猪川祥邦, 園原史訓, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本消化器外科学会総会 Vol. 75回 page： P276 - 5 2020.12

胃癌における周術期化学療法の新知見胃癌に対するS-1補助療法の臨床問題に答えるための多施設データセット解析(New findings on perioperative chemotherapy for gastric cancer Multi-institutional dataset analysis to answer clinical questions of adjuvant S-1 for gastric cancer) Reviewed

Nakanishi Koki, Kanda Mitsuro, Ito Seiji, Mochizuki Yoshinari, Teramoto Hitoshi, Ishigure Kiyoshi, Shimizu Dai, Tanaka Chie, Fujiwara Michitaka, Kodera Yasuhiro

日本消化器外科学会総会 Vol. 75回 page： WS4 - 6 2020.12

MZB1 expression indicates poor prognosis in estrogen receptor-positive breast cancer. Reviewed International journal

Manabu Watanabe, Masahiro Shibata, Takahiro Inaishi, Takahiro Ichikawa, Ikumi Soeda, Noriyuki Miyajima, Yuko Takano, Dai Takeuchi, Nobuyuki Tsunoda, Mitsuro Kanda, Toyone Kikumori, Yasuhiro Kodera, Masato Nagino

Oncology letters Vol. 20 ( 5 ) page： 198 - 198 2020.11

Language：Japanese Publishing type：Research paper (scientific journal)

Breast cancer (BC) is the most common malignant tumor in females. Development of novel biomarkers or therapeutic targets may contribute toward the improvement of a patient's prognosis. Marginal zone B and B1 cell-specific protein (MZB1) is an unfolded protein response-related chaperone and mainly exists in the endoplasmic reticulum of B lymphocytes, although little is known regarding its role in BC cells. The present study aimed to investigate the significance of MZB1 expression in BC. To begin with, MZB1 mRNA expression levels in 13 BC cell lines and two non-cancerous mammary cell lines were evaluated. Next, mRNA and protein expression of MZB1 in BC patient tumor specimens was evaluated to assess the association between expression and clinicopathological factors or prognosis. MZB1 mRNA expression levels were detectable in four estrogen receptor (ER)-positive BC cell lines. When ratios of MZB1 mRNA expression levels between BC and non-cancerous specimens were evaluated, patients with stage III disease exhibited a higher ratio than patients with stage 0/I/II disease (P=0.009). Using immunohistochemistry, patients with ER-positive BC more frequently expressed MZB1, compared with patients with ER-negative BC (P=0.003). In patients with ER-positive BC, patients with MZB1-positive BC experienced shorter disease-free survival (DFS) times than patients with negative BC (P=0.026). Multivariate analysis of DFS demonstrated that MZB1 positivity was an independent prognostic factor (P=0.022). The results of the present study suggested that MZB1 expression may be associated with a more advanced stage of BC. Furthermore, in patients with ER-positive BC, MZB1 may be a potential prognostic marker.

DOI： 10.3892/ol.2020.12059

Web of Science

PubMed

An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. Reviewed International journal

Mitsuro Kanda, Masahiko Koike, Naoki Iwata, Dai Shimizu, Chie Tanaka, Norifumi Hattori, Masamichi Hayashi, Suguru Yamada, Kenji Omae, Goro Nakayama, Yasuhiro Kodera

The oncologist Vol. 25 ( 11 ) page： E1650 - E1654 2020.11

Language：Japanese Publishing type：Research paper (scientific journal)

LESSONS LEARNED: Two courses of neoadjuvant therapy using S-1 plus cisplatin for clinical stage III esophageal squamous cell carcinoma did not achieve expected response rate according to endoscopic evaluation of primary tumors. Subsequent esophagectomy was safely performed. BACKGROUND: In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC). However, 5-fluorouracil plus cisplatin does not benefit cohorts with clinical stage III ESCC, suggesting the need for a more effective regimen. METHODS: A single-arm, open-label phase II trial was conducted to evaluate the safety and efficacy of two courses of neoadjuvant chemotherapy using S-1 plus cisplatin (NAC-SP) for clinical stage III ESCC. The primary endpoint was overall response rate as defined by endoscopic evaluation of primary tumors. RESULTS: We enrolled 26 patients. The completion rate for the two courses of NAC-SP was 61.5%. Grade 3 or higher adverse events were experienced by 38.4% of patients. The treatment response rate according to endoscopic findings, acquired before the second course, was 34.6% and below the expected level (55.0%). The morbidity rate of patients who underwent radical subtotal esophagectomy (96.2%) was 32.0%. Repeat surgery was unnecessary, and surgery-associated deaths did not occur. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 84.6% and 92.2%, respectively. CONCLUSION: We demonstrate safety of NAC-SP, but not its efficacy, for patients with clinical stage III ESCC. Subsequent esophagectomy was safely performed.

DOI： 10.1634/theoncologist.2020-0546

Web of Science

PubMed

Complex roles of the actin-binding protein Girdin/GIV in DNA damage-induced apoptosis of cancer cells. Reviewed International journal

Chen Chen, Atsushi Enomoto, Liang Weng, Tetsuro Taki, Yukihiro Shiraki, Shinji Mii, Ryosuke Ichihara, Mitsuro Kanda, Masahiko Koike, Yasuhiro Kodera, Masahide Takahashi

Cancer science Vol. 111 ( 11 ) page： 4303 - 4317 2020.11

Language：Japanese Publishing type：Research paper (scientific journal)

The actin-binding protein Girdin is a hub protein that interacts with multiple proteins to regulate motility and Akt and trimeric G protein signaling in cancer cells. Girdin expression correlates with poor outcomes in multiple human cancers. However, those findings are not universal, as they depend on study conditions. Those data suggest that multiple aspects of Girdin function and its role in tumor cell responses to anticancer therapeutics must be reconsidered. In the present study, we found that Girdin is involved in DNA damage-induced cancer cell apoptosis. An esophageal cancer cell line that exhibited high Girdin expression showed a marked sensitivity to UV-mediated DNA damage compared to a line with low Girdin expression. When transcriptional activation of endogenous Girdin was mediated by an engineered CRISPR/Cas9 activation system, sensitivity to DNA damage increased in both stationary and migrating HeLa cancer cells. High Girdin expression was associated with dysregulated cell cycle progression and prolonged G1 and M phases. These features were accompanied by p53 activation, which conceivably increases cancer cell vulnerability to UV exposure. These data highlight the importance of understanding complex Girdin functions that influence cancer cell sensitivity to therapeutics.

DOI： 10.1111/cas.14637

Web of Science

PubMed

The efficacy of oxaliplatin combination adjuvant chemotherapy for elderly patients with stage III colorectal cancer. Reviewed

Naomi Hayashi, Mitsuro Kanda, Kenji Omae, Yasuhiro Kodera

Nagoya journal of medical science Vol. 82 ( 4 ) page： 603 - 611 2020.11

Language：Japanese Publishing type：Research paper (scientific journal)

Now we are facing to aging society. We aimed to determine the long-term outcomes receiving adjuvant chemotherapy among elderly patients with stage III colorectal cancer. Elderly patients (≧65 years, n=91) diagnosed as stage III colorectal cancer and received adjuvant chemotherapy were retrieved from the database and classified into two groups according to whether the patient received monotherapy (n=65) or doublet therapy(n=26). Recurrence-free survival and overall survival were compared between the groups. To balance the essential variables, we conducted propensity score matching. After one-to-one propensity score matching, each group consisted of 22 patients. No significant difference was detected by comprehensive geriatric assessment 7. Overall survival was significantly longer in the monotherapy group. Adverse events occurred more frequently in the doublet therapy group. Monotherapy may improve the long-term outcome of elderly patients while the adverse events were less frequent.

DOI： 10.18999/nagjms.82.4.603

Web of Science

PubMed

D2 lymph node dissection confers little benefit on the overall survival of older patients with resectable gastric cancer: a propensity score-matching analysis of a multi-institutional dataset. Reviewed

Takahiro Shinozuka, Mitsuro Kanda, Seiji Ito, Yoshinari Mochizuki, Hitoshi Teramoto, Kiyoshi Ishigure, Toshifumi Murai, Takahiro Asada, Akiharu Ishiyama, Hidenobu Matsushita, Chie Tanaka, Daisuke Kobayashi, Michitaka Fujiwara, Kenta Murotani, Yasuhiro Kodera

Surgery today Vol. 50 ( 11 ) page： 1434 - 1442 2020.11

Language：Japanese Publishing type：Research paper (scientific journal)

PURPOSE: Aging societies comprise an increasing number of elderly gastric cancer (GC) patients. We herein attempted to determine whether D2 lymphadenectomy is beneficial for older GC patients. METHODS: We retrospectively analyzed a multi-institutional dataset including 3484 patients who received surgical resection for GC. For the analysis, we selected patients aged ≥ 80 years who were clinically diagnosed with T1N + or T2-4 GC. To balance the essential variables including the type of gastrectomy and the stage of progression, propensity score matching was conducted, and we compared the background clinical factors and postoperative outcomes of the patients allocated to the D2 (n = 87) and non-D2 (n = 87) dissection groups. RESULTS: The D2 group had significantly longer operative times, more blood loss, and more retrieved lymph nodes (median 32 vs 24, P < 0.001) than the non-D2 group. The D2 group had a greater incidence of intra-abdominal abscesses (grade ≥ II in the Clavien-Dindo classification) than the non-D2 group (3.5% vs 0%, P = 0.040). The overall disease-specific and relapse-free survival rates of the D2 group tended to be poorer than those of the non-D2 group (hazard ratios 1.49, 1.70 and 1.14, respectively). CONCLUSIONS: D2 lymphadenectomy for older patients with GC conferred little benefit regarding overall survival despite an occurrence of increased complication rates.

DOI： 10.1007/s00595-020-02021-7

Web of Science

PubMed

劇症型A群β溶連菌感染症による原発性腹膜炎の1例 Reviewed

砂川祐輝, 猪川祥邦, 山田豪, 園原史訓, 高見秀樹, 林真路, 服部憲史, 神田光郎, 田中千恵, 小林大介, 中山吾郎, 小池聖彦, 藤原道隆, 小寺泰弘

日本臨床外科学会雑誌 Vol. 81 ( 11 ) page： 2399 - 2399 2020.11

膵臓悪性 Reviewed

山田豪, 高見秀樹, 園原史訓, 猪川祥邦, 林真路, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 藤井努, 小寺泰弘

日本消化器外科学会雑誌 Vol. 53 ( Suppl.2 ) page： 316 - 316 2020.11

膵臓化学療法 Reviewed

砂川祐輝, 山田豪, 山中雅也, 鈴木雄之典, 中川暢彦, 加藤吉康, 田中伸孟, 栗本景介, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本消化器外科学会雑誌 Vol. 53 ( Suppl.2 ) page： 311 - 311 2020.11

胃診断 Reviewed

中村俊介, 神田光郎, 清水大, 澤木康一, 田中千恵, 服部憲史, 園原史訓, 高見秀樹, 猪川祥邦, 林真路, 山田豪, 小池聖彦, 小寺泰弘

日本消化器外科学会雑誌 Vol. 53 ( Suppl.2 ) page： 296 - 296 2020.11

Characteristics Associated with Nodal and Distant Recurrence after Curative Resection of Squamous Cell Carcinoma of the Thoracic Esophagus Reviewed

Kanda Mitsuro, Koike Masahiko, Shimizu Dai, Tanaka Chie, Hayashi Masamichi, Hattori Norifumi, Yamada Suguru, Nakayama Goro, Fujiwara Michitaka, Kodera Yasuhiro

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS Vol. 231 ( 4 ) page： E121 - E121 2020.10

予定残肝ICG消失率(ICG-Krem)の術後肝不全発症予測因子としての有用性 Reviewed

砂川祐輝, 山田豪, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 58回 page： O60 - 4 2020.10

血清miRNAシグネチャーを用いた食道扁平上皮癌の早期診断モデルの構築後ろ向き・前向き・多国籍試験 Reviewed

三好人正, 東田周祐, 泉大輔, 神田光郎, 佐藤康史, 六車直樹, 馬場秀夫, 小寺泰弘, ゴエル・アジャイ, 高山哲治

日本癌学会総会記事 Vol. 79回 page： OE15 - 6 2020.10

膵癌における術前治療中のSpan-1の臨床的意義 Reviewed

砂川祐輝, 山田豪, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 清水大, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本臨床外科学会雑誌 Vol. 81 ( 増刊 ) page： 463 - 463 2020.10

胃癌組織中STRA6発現の臨床的意義 Reviewed

中村俊介, 神田光郎, 清水大, 澤木康一, 田中千恵, 服部憲史, 林真路, 山田豪, 小池聖彦, 小寺泰弘

日本癌学会総会記事 Vol. 79回 page： PJ14 - 7 2020.10

予定残肝ICG消失率(ICG-Krem)の術後肝不全発症予測因子としての有用性 Reviewed

砂川祐輝, 山田豪, 園原史訓, 猪川祥邦, 高見秀樹, 林真路, 服部憲史, 神田光郎, 田中千恵, 中山吾郎, 小池聖彦, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 58回 page： O60 - 4 2020.10

食道扁平上皮癌におけるMAGE-D4発現の臨床的意義の検討 Reviewed

澤木康一, 神田光郎, 佐藤雄亮, 清水大, 宇野泰朗, 梅田晋一, 服部憲史, 林真路, 田中千恵, 山田豪, 中山吾郎, 本山悟, 小池聖彦, 藤原道隆, 小寺泰弘

日本癌学会総会記事 Vol. 79回 page： OJ15 - 9 2020.10

ASO Author Reflections: Characteristics Associated with Nodal and Distant Recurrence After Radical Esophagectomy for Squamous Cell Carcinoma of the Thoracic Esophagus. Reviewed International journal

Mitsuro Kanda, Masahiko Koike, Yasuhiro Kodera

Annals of surgical oncology Vol. 27 ( 9 ) page： 3206 - 3207 2020.9

　 PREV - NEXT 　

<KANDA Mitsuro>

Papers - KANDA Mitsuro